Conditions of use
Access to and use of this Web site are subject to the following conditions. Please do not use this Web site unless you agree with these conditions. This Web site has been developed by Grifols Therapeutics Inc. (hereinafter to be referred to as GRIFOLS) and is administrated by the same. We reserve the right to discontinue or to make partial or complete modifications to this Web site or to the General Conditions of Use or to our Privacy Statement. Please note that we may make such changes at our own discretion and without prior announcement. We must therefore ask you, next time you visit this Web site, to view the conditions again and to note any changes or amendments that may have been made.
Surrender of use and benefit
All details, documents and illustrations published on this Web site are the sole property of GRIFOLS. Any permission to use the same is granted on the proviso that the relevant copyright note is displayed on all copies, that such details are only used for personal purposes, that they are not exploited commercially, that the details are not modified in any way and that all illustrations gained from the Web site are only used in conjunction with the accompanying text.
Trademarks and Copyright
All trademarks on this Web site are the property of GRIFOLS, unless otherwise noted or in any other way perceivable as third party rights. Any unauthorized use of these trademarks or other materials is expressly prohibited and constitutes a violation of copyright, trademark law or other industrial property rights.
Limited liability
GRIFOLS has compiled the detailed information provided on this Web site from internal and external sources to the best of its knowledge and belief, using professional diligence. We endeavor to expand and update this range of information on an ongoing basis. The information on this Web site is purely for the purpose of presenting GRIFOLS and its products and services. However, no representation is made or warranty given, either expressly or tacitly, for the completeness or correctness of the information on this Web site. In particular, we must ask you to be aware that this information may no longer be up to date. We therefore recommend that you check any information you obtain from this Web site prior to using it in whatever form. Advice given on this Web site does not exempt you from conducting your own checks on our latest advice—particularly our safety datasheets and technical specifications— and on our products, with a view to their suitability for the intended processes and purposes. Should you require any advice or instructions concerning our products or services, please contact us directly. Users of this Web site declare that they agree to access the Web site and its content at their own risk. Neither GRIFOLS nor third parties involved in the writing, production or transmission of this Web site can be held liable for damage or injury resulting from access or the impossibility of access or from the use or impossibility of use of this Web site or from the fact that you have relied on information given on this Web site.
Web sites of third-party vendors/links
This Web site contains links/references to third-party Web sites. By providing such links, GRIFOLS does not give its approval to their contents. Neither does GRIFOLS accept any responsibility for the availability or the contents of such Web sites or any liability for damage or injury resulting from the use of such contents, of whatever form. Links to other Web sites are provided to Web site users merely for the sake of convenience. Users access such Web sites at their own risk.
Details supplied by yourself
The user of this Web site is fully responsible for the content and correctness of details he or she sends to GRIFOLS as well as for the non-violation of any third-party rights that may be involved in such details. The user gives his or her consent for GRIFOLS to store such details and to use the same for the purpose of statistical analysis or for any other specified business purpose, unless the information involves personal details, going beyond master data or usage data. In particular, GRIFOLS is entitled to use the contents of such messages, including ideas, inventions, blueprints, techniques and expertise contained therein, for any purpose, such as the development, production and/or marketing of products or services and to reproduce such information and make it available to third parties without any limitations.
International users
This Web site is checked, operated and updated by GRIFOLS Therapeutics Inc. at Research Triangle Park, North Carolina (USA). GRIFOLS gives no guarantee that the details presented on this Web site are also correct in places outside the USA, and, in particular, that products and services will be available with the same appearance, in the same sizes or on the same conditions. Should you call up this Web site from a place outside the USA or download contents from such a place, please note that it is your own responsibility to ensure that you act in compliance with local legislation applicable in that place.
Products mentioned on this Web site may come in different packaging, in different package sizes, or with different lettering or markings, depending on the country.
Site with login: access rights
Please note that you are obliged to protect your access rights from unauthorized third-party use and that you must ensure that they cannot be used by others without your authorization. You must notify GRIFOLS immediately if you learn that security has been violated in respect of any details available on the GRIFOLS Web site or if unauthorized persons have obtained your access rights or if you have found indications that such access might become possible.
Updated October 2006
Important Safety Information for GAMUNEX-C
GAMUNEX-C, Immune Globulin Injection (Human), 10% Caprylate/ Chromatography Purified, is approved to treat primary humoral immunodeficiency disease (PI). If you have PI, you may take GAMUNEX-C under the skin (subcutaneously) or in a vein (intravenously.) GAMUNEX-C is also approved to treat other patients with idiopathic thrombocytopenic purpura (ITP) and chronic inflammatory demyelinating polyneuropathy (CIDP), but they may only take it intravenously. You may only take GAMUNEX-C by subcutaneous injection if you have PI.
If you take GAMUNEX-C or a similar Immune Globulin (Human) product intravenously, you could experience serious kidney disease and death. You may have symptoms of decreased urination, sudden weight gain, swelling in your legs (edema), or shortness of breath. You are more likely to develop serious kidney disease if you already have a kidney problem, have Type II diabetes (diabetes mellitus), or are older than 65. You are more likely to develop serious kidney disease if you are dehydrated, have blood poisoning (sepsis), have high protein content in your blood, or if you are receiving other medicines that are harmful to your kidneys. Tell your healthcare professional immediately if your medical history is similar to what we describe here, and especially if you start having any of these symptoms while taking GAMUNEX-C.
You are more likely to develop serious kidney disease if you take an Immune Globulin product that contains sugar (sucrose). GAMUNEX-C does not contain sugar. If your situation makes you more likely to experience serious kidney disease, you should take GAMUNEX-C at the lowest concentration available and the slowest infusion rate that is practical.
Do not take GAMUNEX-C if you have an allergy to Immune Globulin. Tell your healthcare professional if you have had a serious reaction to other medicines that contain Immune Globulin. Also tell your healthcare professional if you have Immunoglobulin A (IgA) deficiency.
You may not take GAMUNEX-C subcutaneously if you have CIDP or ITP. If you have ITP and take GAMUNEX-C subcutaneously, you could experience a very serious and life-threatening black and blue wound (hematoma, which is a large pocket of blood within a tissue).
You could possibly experience high protein content in your blood, thickening of your blood (increased serum viscosity), and low levels of sodium in the blood due to Immune Globulin.
You could possibly experience serious and life-threatening blood clots (thromboembolism) due to Immune Globulin. You might have symptoms of chest pain, shortness of breath, leg pain, or swelling of the legs or feet. You would be more likely to experience a blood clot if you have a history of hardening of the arteries (atherosclerosis), stroke, heart attack, or heart failure (low volume of blood pumped by the heart). You may also be more likely to get a blood clot if you are older than 65, if you have a blood clotting disorder, if you are inactive for long periods of time (such as long bed rest for an infirmity), or if you have thickening of your blood.
You could experience other serious and life-threatening problems due to Immune Globulin. You could get a lung problem called TRALI (transfusion-related acute lung Injury), or have fluid on the lungs (pulmonary edema) that is not the result of heart failure. You could get a blood problem called hemolytic anemia (common symptoms include increased heart rate, fatigue, yellow skin or eyes, and dark colored urine). You could get aseptic meningitis, a type of brain inflammation with symptoms of severe headache, stiff neck, fatigue, fever, sensitivity to light, painful eye movements, nausea, and vomiting.
We do not recommend higher doses, such as 1g/kg for 1-2 days, if you have a condition of higher than normal body fluid volumes or where increasing the body fluid volume may be a concern.
Because GAMUNEX-C is made from human blood, we must warn you that you could get a virus disease, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.After you take GAMUNEX-C, you will have a rise in your blood antibody level which could cause some blood antibody tests to give false results.
The most common side effects in a clinical study with PI patients who got subcutaneous injections of GAMUNEX-C were redness, swelling and itching at the infusion site, and headache, fatigue, pain (including pain in the back, joints arms, and legs) and fever. In clinical studies with PI patients who got GAMUNEX-C intravenously, the most common side effects were headache, cough, nausea, inflammation of the throat (which is the most common cause of sore throat), and redness, swelling and itching at the injection site. In a clinical study with CIDP patients who got GAMUNEX-C intravenously, the most common side effects were headache, fever, chills, high blood pressure, rash, nausea, physical weakness, and loss of strength. In clinical trials with ITP patients who got GAMUNEX-C intravenously, the most common side effects were headache, vomiting, fever, nausea, back pain, and rash.
The most serious side effects in clinical studies were a blood clot to the lung (pulmonary embolism) in one patient with a history of this condition (CIDP), a flare-up of an existing type of anemia (autoimmune pure red cell aplasia) in one patient (PI), and heart inflammation (myocarditis) in one patient (ITP).
Please see full Prescribing Information for Gamunex-C.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Copyright © 2012. Grifols Therapeutics Inc., a subsidiary of Grifols Inc. All rights reserved.